DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Decoy Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.17+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $622.40K
- P/E (TTM)
- –
- Dividend yield
- –
Decoy Therapeutics Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q2 19 | Q1 19 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $227.63K | – | – | – | $0 | – | – | – | – | – | – | – | 100.0% | – |
| Drug Development | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Consumer Operations | – | – | – | – | – | – | – | – | – | – | $164.71K | $104.98K | – | – |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q2 19 | Q1 19 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | -$2.63M | -$2.28M | -$9.03M | -$895.13K | -$965.57K | -$1.72M | -$1.49M | -$1.01M | -$1.47M | -$1.77M | – | – | +172.5% |
| Drug Development | – | – | – | – | – | – | – | – | – | – | -$29.29K | -$384 | – |
| Consumer Operations | – | – | – | – | – | – | – | – | – | – | $11.82K | -$53.11K | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q2 19 | Q1 19 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant | $200.00K | – | – | – | $0 | – | – | – | – | – | – | – | 87.9% | – |
| Net product revenue | – | – | – | – | – | – | – | – | – | – | $163.07K | $104.22K | – | – |
| Other revenue | – | – | – | – | – | – | – | – | – | – | $1.63K | $757 | – | – |
By region
From the segment and revenue-disaggregation notes of Decoy Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.